- Home
- FOUR vs ATAI Comparison
FOUR vs ATAI Comparison
Compare FOUR & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FOUR | ATAI |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | FOUR | ATAI |
|---|---|---|
| Price | $42.03 | $7.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 8 |
| Target Price | ★ $79.05 | $15.88 |
| AVG Volume (30 Days) | 1.8M | ★ 13.7M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,180,000,000.00 | $4,089,000.00 |
| Revenue This Year | $23.83 | N/A |
| Revenue Next Year | $14.30 | N/A |
| P/E Ratio | $27.53 | ★ N/A |
| Revenue Growth | 25.50 | ★ 1227.60 |
| 52 Week Low | $34.56 | $3.27 |
| 52 Week High | $88.50 | $7.45 |
Technical Indicators
Market Signals| Indicator | FOUR | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 46.41 | 62.24 |
| Support Level | $39.78 | $3.32 |
| Resistance Level | $46.17 | N/A |
| Average True Range (ATR) | 2.88 | 0.08 |
| MACD | 0.07 | -0.05 |
| Stochastic Oscillator | 43.27 | 50.23 |
Price Performance
Historical ComparisonAbout FOUR Shift4 Payments Inc.
Shift4 Payments Inc is an independent provider of software and payment processing solutions in the U.S., expanding internationally. Its payments platform offers integrated products and services across in-store, online, mobile and tablet-based channels, including end-to-end payment processing, merchant acquiring services, a proprietary omni-channel gateway, eCommerce capabilities, and reporting tools. The company distributes its services through internal sales teams and partners, including independent software vendors (ISVs) and value-added resellers (VARs). Revenue is predominantly recurring, derived mainly from processing fees and subscription revenue from POS software, business intelligence tools and other technology solutions. The company derives maximum revenue from the United States.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.